Navigation Links
Gene Study Throws Up New Targets for Leishmaniasis

Gene sleuths believe they may have identified potential chinks in the parasite that causes leishmaniasis, a disfiguring and sometimes fatal disease that afflicts some 12 million people around the world . Their comparison of three species of protozoa that cause most cases of leishmaniasis could be a boon for drug engineers, whose budgets for tackling this neglected disease are already slender.

British-led scientists compared the genetic code of Leishmania major, which causes the cutaneous form of leishmaniasis, with those of L. infantum and L. braziliensis, which cause the more dangerous, visceral form of the disease, also called kala-azar. What struck the researchers was that these parasites were very similar genetically, even though they cause very different types of disease.

Each genome has more than 8,000 genes, but only 200 of them differ across the three species. "The degree of similarity between these species was unexpected," said Deborah Smith, a professor at the University of York, northern England. "Perhaps only a few parasite genes are important in determining which type of disease develops after infection, and the host genome plays a major role in clinical outcome."

Another surprise was to find a small number of genes that have never been spotted before. Fellow investigator Chris Peacock described these novel genes as a "short cut" that could help the pharmaceutical quest. "Given their lack of similarity to human genes, they present a limited repertoire of potential targets for drug and vaccine development, allowing researchers to optimise the use of limited resources."

The Leishmania parasite is transmitted in the saliva of sandflies, who tuck in to a blood meal on humans, wild animals and dogs. Around 350 million people in 88 countries are "at risk" of the disease, whose incidence has risen sharply over the past decade, according to the Wellcome Trust Sanger Institute, a British medical research ch arity that led the genome comparison.

The frontline affordable drug, sodium stiboglucomate, marketed as Pentostam, is running into bad resistance problems, leaving many doctors with the option of more expensive treatment that, in the case of visceral leishmaniasis, can cost up to 150 dollars for a four-week course. Cutaneous and mucosal leishmaniasis results in painful, crater-like lesions on the skin.

Visceral leishmaniasis, which affects the spleen and liver, causing fever and weight loss, is fast becoming an opportunistic disease among people whose immune systems have been compromised by the AIDS virus. The study appears on Sunday in the journal Nature Genetics.


'"/>




Related medicine news :

1. Tomato Sauce reduces Cancer Risk- Study
2. Study on obesity and heart failure
3. National Lung Study in the process
4. Study casts doubt on keyboard ills
5. Study reveals how stress can make you sick
6. Study reveals how stress can make you sick
7. Study supports vegetable diet
8. Study to look at early surgery to treat epilepsy
9. Its Never Too Late to Stop Smoking,Study Finds
10. New Technique to Study Infants Brain.
11. Groundbreaking Study Gives Hope For Patients With Kidney Cancer
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/27/2016)... ... June 27, 2016 , ... TherapySites, the ... affiliation with Tennessee Counseling Association. This new relationship allows TherapySites to ... Counseling Association, adding exclusive benefits and promotional offers. , "TCA is extremely excited ...
(Date:6/26/2016)... ... ... Quality metrics are proliferating in cancer care, and are derived from many ... the beholder, according to experts who offered insights and commentary in the current issue ... the full issue, click here . , For the American Society of Clinical ...
(Date:6/26/2016)... ... ... blind and certified personal trainer is helping to develop a weight loss fitness plan that ... the two major problems leading the fitness industry today:, , All ... They don’t eliminate all the reasons people quit their exercise program , ...
(Date:6/25/2016)... ... , ... The temporary closing of Bruton Memorial Library on June 21 due to a possible ... often overlooked aspect of head lice: the parasite’s ability to live away from a human ... but a necessary one in the event that lice have simply gotten out of control. ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... HILL, N.C. , June 24, 2016 /PRNewswire/ ... healthcare decisions and regulators/payers have placed more emphasis ... new environment, patient support programs in the pharmaceutical ... for patients, medications. Consequently, pharmaceutical companies are focusing ... ensure they are providing products and services that ...
(Date:6/24/2016)... FRANCISCO, Calif. , June 24, 2016 /PRNewswire/ ... ), a biopharmaceutical company developing novel therapeutics for ... unmet needs, today announced the closing of its ... of common stock, at the public offering price ... in the offering were offered by GBT. GBT ...
(Date:6/24/2016)... , June 24, 2016 ... Markets has announced the addition of the " ... offering. This ... and provides an updated review, including its applications in ... the total market, which includes three main industries: pharmaceutical ...
Breaking Medicine Technology: